The findings illustrate a clear trend: older, established chemotherapy regimens (which are mostly generic drugs) offer good value, whereas newer therapies (bevacizumab, immunotherapies, targeted drugs) dramatically increase costs and often yield ICERs above commonly accepted thresholds.
← all excerpts
Cost-effectiveness of chemotherapy for advanced and recurrent cervical cancer: a systematic review.
1
—
—